NMD Pharma progresses it’s Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma is currently conducting a Phase I/IIa clinical trial with its lead drug candidate, NMD670, in patients with Myasthenia Gravis.  The trial is taking place at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands, and is being led by Principal Investigator Dr Geert Jan Groeneveld, CHDR’s Chief Scientific Officer and Chief Medical Officer.

Further information on the study can be found on The Netherlands Trial Register: https://www.trialregister.nl/trial/8692

Patients interested to learn more can contact Centre for Human Drug Research by visiting the website: https://proefpersoon.nl/myasthenia-gravis-deel-c (in Dutch), or by email or phone: recruit@chdr.nl or +31 71-5246400